PainReform Shares Are Trading Lower After the Company Announced That Data Pertaining to the Subsequent 24-hour Period Needed to Assess the Primary Endpoint of the Phase 3 Clinical Trial Evaluating PRF-110 Is Currently Unclear.
PainReform Shares Are Trading Lower After the Company Announced That Data Pertaining to the Subsequent 24-hour Period Needed to Assess the Primary Endpoint of the Phase 3 Clinical Trial Evaluating PRF-110 Is Currently Unclear.
Painreform的股票在公司宣佈與評估PRF-110的三期臨床試驗主要終點相關的後續24小時的數據目前尚不清楚後，交易價格下跌。
PainReform Shares Are Trading Lower After the Company Announced That Data Pertaining to the Subsequent 24-hour Period Needed to Assess the Primary Endpoint of the Phase 3 Clinical Trial Evaluating PRF-110 Is Currently Unclear.
Painreform的股票在公司宣佈與評估PRF-110的三期臨床試驗主要終點相關的後續24小時的數據目前尚不清楚後，交易價格下跌。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間